Podcast Episodes
Back to SearchFrom “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care
Recent advances in metastatic urothelial carcinoma have meant that optimistic outcomes are “not as much of a fairytale,” says Robert Dreicer, MD, dep…
2 years ago
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression
Recent approvals by the U.S. Food and Drug Administration (FDA) and findings from pivotal clinical trials have changed care for patients with breast …
2 years, 1 month ago
Controversies, Difficult Questions Arise in NSCLC Amid New Data
Recent data on the use of immunotherapy and targeted treatments in patients with advanced non-small cell lung cancer (NSCLC) have introduced a myriad…
2 years, 1 month ago
What FDA Approval of Belzutifan Means for Kidney Cancer Care
Belzutifan was recently approved by the U.S. Food and Drug Administration (FDA) for use in previously treated adults with advanced renal cell carcin…
2 years, 1 month ago
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer
CDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug dev…
2 years, 2 months ago
Which FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 2023?
From compelling data presented at the San Antonio Breast Cancer Symposium to the recent U.S. Food and Drug Administration approval of capivasertib,…
2 years, 3 months ago
“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment Advances
From the use of prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) to advancements in targeted treatments, prostate cancer …
2 years, 3 months ago
Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong Benefit
Results of the recent EMBARK study show that both enzalutamide plus leuprolide and enzalutamide monotherapy significantly improved metastasis-free su…
2 years, 3 months ago
ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023
Studies involving high-risk, early-stage ER-positive breast cancer are among the most eagerly anticipated at this year’s San Antonio Breast Cancer Sy…
2 years, 4 months ago
Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons Learned
Last month, a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) determined that progression-free survival (PFS) could…
2 years, 4 months ago